The conjugation of doxaliform to alpha(nu) beta3 (alpha(nu)beta(3))targeting peptides provides a potential therapeutic alternative for the management of alpha(nu)beta(3)-overexpressing breast carcinomas. Journal Article uri icon


publication date

  • January 1, 2005

Date in CU Experts

  • September 9, 2013 9:41 AM

Full Author List

  • Vellon L; Menendez JA; Burkhart DJ; Kalet BT; Koch TH; Lupu R

author count

  • 6

Other Profiles

International Standard Serial Number (ISSN)

  • 0167-6806

Additional Document Info

start page

  • S71

end page

  • S72


  • 94